This website is intended exclusively for healthcare professionals and medical device manufacturers.
By accessing this site, you confirm that you belong to one of its of these categories and understand that the information provided is specifically intented for a professional audience.
"JOIN THE LEADERS OF AESTHETIC INJECTABLES"
Benjamin Ascher, MD, is a board-certified plastic surgeon, member of the French, American, and International Societies of Plastic, Reconstructive and Aesthetic Surgery (SOFCPRE, SOFCEP, ASPS, ISAPS).
A former chief resident, Hospitals of Paris assistant and Chairman & Head of the “IENA Aesthetic Surgery Clinique” in Paris, France.
He is the Founder and President of:
IMCAS company, a world leader in medical conferences (Paris, Bangkok, Bali, Cancun, Cartagena, Mumbai, Goa, Shanghai), dealing with the interface between Plastic Surgery, Cosmetic Dermatology and Aesthetic Medicine.
ThinkIn company: leader with VIP hands-on classes dedicated to anatomy, minimal invasive live treatments, injection and threads simulator, and ultrasound-guided injections.
He is a member of the International Editorial Board of the Aesthetic Surgery Journal (ASJ), Section Editor of the Aesthetic Plastic Surgery Journal (APSJ) and member of the Editorial Board for Journal of Cosmetic and Laser Therapy, as well as author of 200 original articles published in referenced journals, and peer-reviewed articles.
He works extensively in research and clinical studies related to aesthetic surgical & medical procedures (toxins, fillers, anatomy, ultrasonography, regenerative medicine, lasers & energy-based devices for skin tightening and lipolysis, threads, fat grafting, facelift and eyelid surgery).
The Medical Aesthetic Injectable Summit sets itself apart by being specifically dedicated to injectables ecosystem in the field of medical aesthetics. This specificity gives it a particular importance, but it is not the central element of this summit. The very essence of this gathering lies in its unique nature and in its objective to promote the acquisition of highlevel economic & scientific knowledge, allied with powerful networking, distinct from the events and logistics of the major congresses that bring together the largest populations in our profession, such as IMCAS.
Another fundamental aspect is its resolutely practical orientation. Thanks to the resources deployed, this summit offers an exceptional opportunity for practical application, networking and making appointments over a 48-hour period, making it a truly unique event.
Finally, what really sets MAIS appart is the whole “business & science together” aspect. The summit covers all the processes an injectable goes through (from clinical research to regulations) before hitting the clinics. It also introduces innovative novelties from startups and products in the pipeline.
The originality of this summit lies in the diversity of the three target populations, unlike traditional congresses, which attract a homogeneous audience. The first group is made up of doctors, leaders in their field, whose main role is to disseminate information. They are not product creators, but the users and teachers of the techniques derived from these products.
The second group is made up of PhDs working in research laboratories, the real inventors of patents and creators of the majority of essential products in the field of injectables, toxins and fillers. These researchers are rarely present at our usual conferences.
The third population is an alliance between the usual companies present at these events and other key players. This time, the companies will play a different role, working in practical collaboration with regulators, financiers (funds, private equity, banks), start-ups seeking to attract investors for their development, as well as distributors and regulatory experts. Regulation will be approached in a novel way, with companies explaining the specific challenges associated with European, American, Chinese and Korean commissions.
In addition, a platform called Speed Matching will be launched at the beginning of September, enabling participants to identify themselves, present their biographies and specify their expectations, thus facilitating effective interaction and collaboration.
For this Medical Aesthetic Injectable Summit (MAIS), we have chosen to concentrate our efforts on the two major pillars of toxins and fillers. As far as fillers are concerned, our approach encompasses a vast range of products, including hyaluronic acid, nonhyaluronic acid fillers, as well as everything to do with injectable regenerative medicine, artificial intelligence and gene therapy.
Together, they form a microcosm of very high-level information and data. The second essential aspect of the summit concerns economic information, provided by companies specialising in market analysis such as BCG, Cetas HealthCare, Wall Street, etc.
The originality of this event lies in its multidisciplinary nature, going beyond a simple gathering of doctors. It has been conceived and organised by four entities with complementary and distinct profiles.
Firstly, we have a plastic surgeon, Dr Ascher. Secondly, an internationally renowned dermatologist in the field of aesthetic and medical dermatology, Marina Landau. Thirdly, Humberto Antunes, former CEO of Galderma and currently head of the Gore Range Capital fund, who will also be taking part in the summit. Lastly, Fauad Hassan, PhD and product developer, who is renowned for having sold a fast-acting toxin to ABBVIE, bringing indepth expertise in toxin development.
The speed matching concept is unprecedented in our profession. This innovative platform is based on the use of artificial intelligence algorithms, making it much easier to organise appointments. Thanks to this system, participants know well in advance the list of people they will be meeting, optimising interactions and exchanges.
Generally speaking, tackling the issue of artificial intelligence means thinking about the challenges it poses. AI represents a form of intelligence that is far superior to our own. The major challenge is to determine how to control it and ensure that doctors are not left behind, but remain at the heart of development. This challenge is immense and concerns the entire medical sector, including plastic surgeons, dermatologists and aesthetic doctors, as well as our flagship areas.
We need to consider the impact of AI on all applications used before, during and after treatment, as well as on robotics related to surgery and, in the near future, injections. Simulation and augmented reality, integrated with AI, offer excellent opportunities to strengthen teaching functions and provide numerous assets for doctors, who will thus become “augmented doctors”.
All these aspects will be addressed, while always keeping in mind the need to refocus the debate on the development of injectables.
